Drug Discovery – Page 2

AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

2 months ago talkbio0Tagged AI Proteins, Artificial Intelligence, BioCapital, Biotechnology, de novo miniproteins, Drug Discovery, Religious Missions, Santé Ventures, Series A financing, Synthetic Biology, therapeutic protein

AI Proteins; Series A financing; de novo miniproteins; protein therapeutics; artificial intelligence; drug discovery; Mission BioCapital; Santé Ventures; synthetic biology; biotechnology

Navigating JPM 2026: Biotech/Biopharma Trends, Policy Impacts, and Forward Outlook

2 months ago talkbio0Tagged Biopharma, dealmaking, Drug Discovery, financing strategy, Health Policy, innovation, JPM, trends qualifier

JPM 2026; biotech trends; biopharma trends; healthcare policy; AI in drug discovery; financing strategy; dealmaking; innovation

Friday Five: Lilly Expands Zepbound’s DTC Reach, NVIDIA Powers Drug Discovery at Lilly and Verily, and OpenAI Advances Pharma AI Initiatives

3 months ago talkbio0Tagged AI supercomputer, direct-to-consumer ( DTC ), Drug Discovery, federated learning, LillyDirect, NVIDIA, OpenAI, Pharma AI, TuneLab, Walmart partnership, Zepbound

LillyDirect; Zepbound; Direct-to-consumer (DTC); NVIDIA; AI supercomputer; Verily; OpenAI; Pharma AI; Drug discovery; Walmart partnership; TuneLab; Federated learning

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

3 months ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing

From JP Morgan to the Next Wave: What’s Driving Biotech in 2026

3 months ago talkbio0Tagged 2026, Artificial Intelligence, Drug Discovery, Hematology (discipline), Investments, J.P. Morgan Healthcare Conference, M&A activity, Neoplasms, Neuropsychology, regulatory science, trends qualifier

J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

4 months ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

4 months ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

5 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs